Nagose Vaishali B, Kodate Purnima M, Kumbhalkar Dinkar T, Rathod Shivanand S, Nayak Suprita P
Department of Pathology, Government Medical College and Hospital, Nagpur, India.
Department of Pathology, Government Medical College, Sindhudurg, India.
Indian J Hematol Blood Transfus. 2024 Apr;40(2):281-288. doi: 10.1007/s12288-023-01703-9. Epub 2023 Oct 18.
To determine whether there is higher degree of platelet and/ or coagulation activation in sickle cell anaemia (SS) patients in complications and with clinical risk factors. A cross sectional study was conducted at a tertiary health care centre in central India with study groups: sickle cell disease (SCD): sickle cell anaemia (SS) and sickle cell trait (AS) consisting of 100 subjects each and controls (AA) with 40 subjects. Platelet aggregation (PA) with ADP, collagen and epinephrine, PT and aPTT were performed in all subjects and PA with ristocetin in ten candidates of each group. ANOVA and student's unpaired t test were used to compare PA and coagulation profile of the three groups with respect to age groups, gender, present diagnosis, history of complications, frequency of hospital admissions (high ≥ 3/year) and frequency of blood transfusion (high > 2/year). The max PA% with ADP was significantly less in SS patients in steady state, which was even lesser in those having symptoms, complications in past/ present, high-frequency hospital admission and > 2 blood transfusions per year subgroups, as compared to all other groups and subgroups, but not consistently with collagen and epinephrine. The max PA % with ristocetin was least in SS with complications. No statistically significant difference in PT and aPTT values among the various clinical risk subgroups and groups was found. SCD patients can be monitored by using PA with ADP for their timely and better management. PA with ADP, PT and aPTT should be added to the workup of these patients for improved prognostication.
为了确定镰状细胞贫血(SS)患者在出现并发症并伴有临床危险因素时是否存在更高程度的血小板和/或凝血激活。在印度中部的一家三级医疗中心进行了一项横断面研究,研究组包括:镰状细胞病(SCD):镰状细胞贫血(SS)和镰状细胞性状(AS),每组各100名受试者,以及对照组(AA)40名受试者。对所有受试者进行了用二磷酸腺苷(ADP)、胶原蛋白和肾上腺素诱导的血小板聚集(PA)检测、凝血酶原时间(PT)和活化部分凝血活酶时间(aPTT)检测,并对每组的十名受试者进行了用瑞斯托霉素诱导的PA检测。使用方差分析和学生未配对t检验比较三组在年龄组、性别、当前诊断、并发症史、住院频率(高≥每年3次)和输血频率(高>每年2次)方面的PA和凝血指标。与所有其他组和亚组相比,处于稳定状态的SS患者用ADP诱导的最大PA%显著降低,在有症状、过去/现在有并发症、高频住院和每年输血>2次的亚组中甚至更低,但与胶原蛋白和肾上腺素诱导的情况不一致。有并发症的SS患者用瑞斯托霉素诱导的最大PA%最低。在不同临床风险亚组和组之间,PT和aPTT值未发现统计学上的显著差异。可以通过使用ADP诱导的PA来监测SCD患者,以便及时进行更好的管理。应将ADP诱导的PA、PT和aPTT添加到这些患者的检查中,以改善预后。